Bayer sells H.C. Starck to investors for $1.57B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Bayer |
Investors |
$1.57B sale |
Bayer has struck a deal to sell its material sciences division, H.C. Starck, to a group of investors for €1.2 billion. |
|
Illumina |
Solexa |
$600M buyout |
Solexa specializes in whole genome sequencing. |
|
Actelion |
CoTherix |
$420M buyout |
Through the acquisition of CoTherix, Actelion will further its PAH therapy. |
|
Biota |
Boehringer Ingelheim |
$102M collaboration deal |
Australia's Biota will collaborate with Germany's Boehringer Ingelheim on a new therapy for Hepatitis C. |
|
Vectura |
Innovata |
$243M buyout |
Vectura has inked a deal to buy Innovata for $243 million, exchanging one Vectura share for every three shares of Innovata. |
|
Merck |
Advinus |
$74.5M deal |
India's Advinus has been brought on by Merck to handle drug research projects. |
|
Pharmion |
Cabrellis Pharmaceuticals |
$59M deal |
Pharmion has acquired a mid-stage lung cancer therapy--amrubicin--in its deal to buy Cabrellis Pharmaceuticals for $59 million up front. |
|
Hospira |
Stada Arzneimittel |
$55M development deal |
The companies announced plans to develop a biosimilar version of erythropoietin, which is used to treat anemia in dialysis and cancer patients. |
|
Crucell |
3i and SEB |
$51.8M acquisition |
Dutch biotech Crucell announced that it will acquire Sweden-based SBL Vaccin from 3i and SEB for €39.4 million. |
|
GlaxoSmithKline |
NeuroSearch |
$39M buyout |
NeuroSearch will be responsible for development work on some drug candidates through Phase IIa, with Glaxo taking over late-stage development. |
|
Bradley Pharmaceuticals |
BioSante |
$14M licensing deal |
Bradley Pharmaceuticals has agreed to license BioSante's experimental gel for hot flashes for $3.5 million up front and up to $10.5 million in milestones. |
|
Neurogen |
Wyeth |
$3M licensing deal |
Neurogen has paid $3 million as an initial licensing fee for Wyeth's Applindore. Neurogen will focus on the drug as a treatment for Parkinson's disease. |
|
Kiadis |
Celmed BioSciences |
Merger |
The companies will focus on new oncology therapies. |
|
Eli Lilly |
Applied NeuroSolutions |
Development deal |
Applied NeuroSolutions will work with Eli Lilly to develop new Alzheimer's drugs. |
|
Merck KGaA |
Chi-Med |
Deal |
Merck KGaA has inked a deal that gives the German drug company access to Chi-Med's large Shangha research center as well as its library of botanical compounds. |
|
Merieux Alliance |
Shantha Biotechnics |
Acquisition |
The deal gives Merieux a new development center for vaccines, therapeutic proteins and monoclonal antibodies. |